Murepavadin

Summary

Murepavadin (CHEMBL3946483) is a phase-3 clinical-stage protein; indicated across 2 conditions including pneumonia and kidney disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 2 conditions
• Clinical trials: 9
• Chemistry: 1553.8 Da · C73H112N22O16

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3946483
Name	Murepavadin
Type	Protein
Max phase	3
FDA approved	no
PubChem CID	91824766
Molecular formula	C73H112N22O16
Molecular weight	1553.8
InChIKey	RIDRXGOBXZLKHZ-NZUANIILSA-N

SMILES: CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@@H]2C(=O)N3CCC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC4=CNC5=CC=CC=C54)[C@@H](C)O)CO)C)CCN)CCN)CC6=CNC7=CC=CC=C76)CCN)CCN)CCCN)CCN

IUPAC name: (3R,9S,12S,15S,18S,21S,24S,27R,30S,33S,36S,39S,42S,45S)-15,18,24,27,33-pentakis(2-aminoethyl)-30-(3-aminopropyl)-36-[(2S)-butan-2-yl]-42-[(1R)-1-hydroxyethyl]-9-(hydroxymethyl)-21,39-bis(1H-indol-3-ylmethyl)-12-methyl-1,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazatricyclo[43.3.0.03,7]octatetracontane-2,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecone

Also known as: Murepavadin, Murepavadina, Murepavadine, POL-7080, Pol7080, POL7080, RO-7033877, Ro7033877, RO7033877, MUREPAVADIN

Patent coverage: 44 distinct patent families (117 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
pneumonia	3	MONDO:0005249	EFO:0003106
kidney disorder	1	MONDO:0005240	EFO:0003086

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE1	5
PHASE3	2
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03409679	PHASE3	TERMINATED	Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa
NCT03582007	PHASE3	TERMINATED	Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas
NCT02096315	PHASE2	TERMINATED	Safety, Efficacy and PK/PD of POL7080 in Patients With Exacerbation of Non-cystic Fibrosis Bronchiectasis.
NCT02096328	PHASE2	COMPLETED	Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia
NCT02110459	PHASE1	COMPLETED	Pharmacokinetics and Safety of POL7080 in Patients With Renal Impairment
NCT02156323	PHASE1	COMPLETED	A Phase 1 Clinical Study in Healthy Volunteers to Investigate the Drug-drug Interaction Between Multiple Doses of RO7033877 and Multiple Doses of Colistin Methanesulfonate Sodium (CMS)
NCT02165293	PHASE1	COMPLETED	A Single Center Study to Evaluate the Penetration of RO7033877 Into the Lung in Healthy Volunteers
NCT02165332	PHASE1	COMPLETED	A Two-part, Single-dose, Randomized Study to Evaluate the Safety of Supra-therapeutic Doses of RO7033877 and to Investigate the Effect of RO7033877 on the QTc Interval
NCT02897869	PHASE1	COMPLETED	DDI Study to Investigate Interaction Between Amikacin and POL7080

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).